Vanguard Group Inc. lifted its position in ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) by 1.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 618,763 shares of the company’s stock after acquiring an additional 9,416 shares during the period. Vanguard Group Inc. owned 3.43% of ProPhase Labs worth $4,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded shares of ProPhase Labs to a “sell” rating in a research report on Wednesday, June 26th.
Read Our Latest Analysis on ProPhase Labs
ProPhase Labs Stock Up 10.6 %
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Why is the Ex-Dividend Date Significant to Investors?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.